GKB Ophthalmics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve the unaudited Standalone and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics has informed BSE that its Board of Directors will meet on February 12, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26). The trading window for designated persons has been closed since January 1, 2026, and will reopen 48 hours after the results are submitted to the stock exchange. This is a standard advance notice filed under SEBI's Listing Obligations and Disclosure Requirements (Regulation 29). No actual financial numbers have been disclosed in this filing.
No direct impact on shareholders from this notice alone. Investors should watch for the actual Q3 FY26 results on/after February 12, 2026, for any meaningful revenue, profit, or margin movement in the eye-care/lens manufacturing business.